{"id":"W4378781365","doi":"10.1080/21678421.2023.2216223","title":"COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success","year":2023,"lang":"en","type":"article","venue":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta; Montreal Neurological Institute and Hospital","funders":"Grupo Ferrer Internacional, S.A; Astellas Pharma; Motor Neurone Disease Association; National Institute for Health and Care Research; University of Alberta; Apellis Pharmaceuticals; King's College London; Denali Therapeutics; Mitsubishi Tanabe Pharma Corporation; Agence Nationale de la Recherche; Hope Foundation; Acorda Therapeutics; Pfizer; UCB Pharma; Fondation Brain Canada; Medical Research Council; Biogen; Cytokinetics; Economic and Social Research Council; Deutsche Gesellschaft für Neurologie; Sanofi; Alexion Pharmaceuticals","keywords":"Physical therapy; Medicine; Population; Rating scale; Clinical trial; Amyotrophic lateral sclerosis; Courage; Placebo; Randomized controlled trial; Psychology; Disease; Internal medicine; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004778443,0.001832891,0.002608096,0.0007476535,0.0008664965,0.001159808,0.0008568341,0.003155521,0.01214408],"category_scores_gemma":[0.003954014,0.0007402552,0.001341458,0.0004756663,0.001422393,0.001568703,0.0007710496,0.002529034,0.001090478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004690525,"about_ca_system_score_gemma":0.002164008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000366132,"about_ca_topic_score_gemma":0.001003892,"domain_scores_codex":[0.9978085,0.001344461,0.0001382577,0.0003197603,0.0002122044,0.000176908],"domain_scores_gemma":[0.9976567,0.000832492,0.0006137331,0.0001480519,0.0001992336,0.000549841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9380219,0.02649347,0.000608168,0.001117119,0.0005301957,0.0000480575,0.00009699154,0.0004257335,0.0048573,0.0003858784,0.001453134,0.02596211],"study_design_scores_gemma":[0.9292345,0.06836788,0.0006750046,0.00003423695,0.000102943,0.0000177075,0.0000108756,0.0003287109,0.0002958358,0.0001650418,0.0007564228,0.00001089141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.888302,0.006488007,0.009527258,0.001542322,0.001668219,0.0843235,0.001865875,0.0009841635,0.005298577],"genre_scores_gemma":[0.854408,0.002192609,0.02563343,0.00283892,0.001042773,0.1073383,0.0008363823,0.0001384901,0.005571112],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01214408,"threshold_uncertainty_score":0.04062605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1337870059088949,"score_gpt":0.3642564715540338,"score_spread":0.2304694656451389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}